NCT05205668View on ClinicalTrials.gov

Study of F-652 in Subjects With Corona Virus Disease 2019 (COVID-19) Pneumonia

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 8, 2022

Primary Completion Date

April 8, 2022

Study Completion Date

April 8, 2023

Conditions
COVID-19 Pneumonia
Interventions
BIOLOGICAL

F-652

IL-22 fusion protein administered intravenously

BIOLOGICAL

Placebo

Placebo administered intravenously

Sponsors
All Listed Sponsors
lead

EVIVE Biotechnology

INDUSTRY